4.7 Article

Exploring the role of senescence inducers and senotherapeutics as targets for anticancer natural products

Journal

EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 928, Issue -, Pages -

Publisher

ELSEVIER
DOI: 10.1016/j.ejphar.2022.174991

Keywords

Cancer; Cellular senescence; Natural products; Senotherapeutics; Senolytic agents

Funding

  1. Research Grants Council (RGC) of the Hong Kong Special Administrative Region, China [PF19-37232]
  2. [P30 ES005022]

Ask authors/readers for more resources

Cancer is a deadly disease that requires urgent drug discovery. Cellular senescence has gained attention for its link to cancer therapy. Senescent cells produce harmful effects and senescence inducers and senotherapeutics have been found to inhibit cancer.
During the last few decades, cancer has remained one of the deadliest diseases that endanger human health, emphasizing urgent drug discovery. Cellular senescence has gained a great deal of attention in recent years because of its link to the development of cancer therapy. Senescent cells are incapable of proliferating due to irreversibly inhibition of the initiation of the cell cycle pathways. However, senescent cells aggregate in tissues and produce a pro-inflammatory secretome called senescence-associated secretory phenotype (SASP) that can cause serious harmful effects if not managed properly. There is mounting evidence that senescent cells lead to various phases of tumorigenesis in various anatomical sites, owing mostly to the paracrine activities of the SASP. Therefore, a new treatment field called senotherapeutics has been established. Senotherapeutics are newly developed anticancer agents that have been demonstrated to inhibit cancer efficiently. In light of recent findings, several promising natural products have been identified as senescence inducers and senotherapeutics, including, miliusanes, epigallocatechin gallate, phloretin, silybin, resveratrol, genistein, sulforaphane, quercetin, allicin, fisetin, piperlongumine, berberine, triptolide, tocotrienols and curcumin analogs. Some of them have already been validated through preclinical trials and exert an enormous potential for clinical trials. This review article focuses on and summarizes the latest advances made on cellular senescence and its potential as a target for cancer treatment and highlights the well-known natural products as senescence inducers and senotherapeutics for cancer treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available